Comparative performance of traditional and novel adiposity indices for predicting insulin resistance and metabolic syndrome in Chinese women with polycystic ovary syndrome
Abstract
Objective: This study aimed to comprehensively evaluate and compare the predictive performance of seven adiposity indices-both traditional (waist-to-hip ratio, WHR; waist-to-height ratio, WHtR) and novel (visceral adiposity index, VAI; Chinese visceral adiposity index, CVAI; lipid accumulation product, LAP; triglyceride-glucose index, TyG; cardiometabolic index, CMI)-for identifying insulin resistance (IR) and metabolic syndrome (MetS) in a large cohort of Chinese women with polycystic ovary syndrome (PCOS).
Methods: This secondary analysis enrolled 944 Chinese women with PCOS from the PCOSAct trial. IR was defined as homeostasis model assessment of insulin resistance (HOMA-IR) ≥ 2.69, and MetS was diagnosed in accordance with Chinese female-specific criteria. Receiver operating characteristic (ROC) curve analysis was applied to assess the discriminatory ability of each adiposity index, and correlations between these indices and metabolic, reproductive, hepatic as well as renal parameters were analyzed.
Results: The prevalence of IR and MetS in this cohort was 50 and 15.68%, respectively. All adiposity indices were significantly correlated with key metabolic parameters (all p < 0.001). For predicting IR, LAP (AUC = 0.815) and CVAI (AUC = 0.813) showed the highest diagnostic accuracy. For predicting MetS, CMI (AUC = 0.905), LAP (AUC = 0.898) and VAI (AUC = 0.893) presented the optimal predictive efficacy. Additionally, these adiposity indices were significantly correlated…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 944 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.